Intavis at 2026 SITC EU Immuno-Oncology Drug Development Summit

Intavis at the 2026 SITC EU Immuno-Oncology Drug Development Summit

Intavis Peptide Services is pleased to participate in the 2026 SITC EU Immuno-Oncology Drug Development Summit, taking place from September 3 to 4, 2026, at the Agora Cancer Research Center in Lausanne, Switzerland.

Organized by the Society for Immunotherapy of Cancer (SITC), the summit brings together the European immuno-oncology community to discuss the next wave of innovative IO therapeutics and how promising new approaches can be efficiently translated into clinical testing. The program provides a forum for experts from biotechnology, pharmaceutical companies, academia, regulatory agencies, medicine, and investment to exchange knowledge and explore best practices in modern immuno-oncology drug development.

What to expect at the 2026 SITC EU Immuno-Oncology Drug Development Summit:

• Scientific presentations and expert discussions on emerging immuno-oncology therapies
• Insights into therapies beyond PD-1, including multi- and bispecific antibodies
• Updates on cancer vaccines, TCR T-cell therapies, and immune cell engagers
• Sessions on engineered immune cell therapies and novel approaches for solid tumors
• Discussions on antibody-drug conjugates (ADCs) and IO combination strategies
• Perspectives on clinical trial design, preclinical models, and global regulatory requirements
• Sessions covering radioimmunotherapy, biomarkers, immunogenic cell death, and next-generation IO platforms
• Discussions on biotech innovation, investment, and collaboration between Europe and the United States
• Networking opportunities with scientists, clinicians, biotechnology and pharmaceutical professionals, regulators, and investors

Intavis Peptide Services will be represented at the summit by Dr. Oliver Reimann and Dr. Van Tuan (Marco) Trinh. They will be available to discuss our customized peptide synthesis services and how Intavis Peptide Services can support immuno-oncology research, cancer vaccine development, immune monitoring, assay development, antibody research, and other peptide-based applications.

Whether you are developing novel immunotherapies, advancing cancer vaccine programs, working on immune-response studies, or looking for a reliable partner for custom peptide synthesis, the SITC EU Immuno-Oncology Drug Development Summit offers an excellent opportunity to meet our team and discuss how Intavis Peptide Services can support your research and development projects.

Meet us in Lausanne and connect with Oliver and Marco to explore opportunities for future collaboration.

We look forward to meeting you in Lausanne!